FibroGen Reports Second Quarter 2019 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
FibroGen (FGEN) Posts Large Q2 EPS, Rev Beat
August 8, 2019 5:00 PM EDTFibroGen (NASDAQ: FGEN) reported Q2 EPS of $1.26, $1.77 better than the analyst estimate of ($0.51). Revenue for the quarter came in at $191.57 million versus the consensus estimate of $29.03 million.
This has been a very productive quarter with the achievement of multiple regulatory and clinical... More
